News & Events
-
January 21, 2021
From the Regulatory Affairs Professional Society (RAPS): FDA’s CURE ID app gets a COVID-19 refresh
An online case reporting platform has been optimized for COVID-19 and will be the springboard for a new public-private drug repurposing collaboration. The CURE ID online platform was developed to allow clinicians to report off-label uses of drugs to treat infectious diseases, with the goal of generating hypotheses for further study of difficult-to-treat infectious...... -
November 2, 2020
C-Path and EATRIS To Collaborate on RDCA-DAP
C-Path has signed a Memorandum of Understanding with EATRIS, the European infrastructure for translational medicine, to accelerate drug development for rare diseases by increasing the efficiency of translation of potential therapeutics through preclinical and clinical development. C-Path and NORD co-hosted a virtual workshop on October 19, 2020 highlighting the milestones reached and future plans for...... -
March 26, 2020
ePRO Consortium Announces Open Access Article
In collaboration with the DIA Study Endpoints Community, C-Path’s ePRO Consortium is pleased to announce the open access article “Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials” is available online in the April 1, 2020 issue of Contemporary Clinical Trials. This article provides recommendations for the structure and content of an evidence dossier aimed at supporting a clinical trial endpoint derived from mobile sensor data as fit-for-purpose in regulatory decision making.
Link to article: https://www.contemporaryclinicaltrials.com/article/S1551-7144(20)30040-9/fulltext
-
December 2, 2019
Workshop Summary, Advancing the Development and Implementation of Analysis Data Standards, Now Available
C-Path is proud to announce the availability of the workshop summary, Advancing the Development and Implementation of Analysis Data Standards: Key Challenges and Opportunities. The workshop, in collaboration with the Duke-Margolis Center for Health Policy and the Food and Drug Administration (FDA), was planned with the support of C-Path data standard expertise, and included a...... -
October 29, 2019
U.S. Senator Martha McSally Visits C-Path
U.S. Senator Martha McSally (Arizona) visited Tucson-based Critical Path Institute (C-Path) Friday, October 25, to learn more about its mission to accelerate drug development. C-Path, founded in 2005, aims to catalyze the development of new approaches that advance medical innovation and regulatory science through collaboration and public and private partnerships. “C-Path is a unique leader......